Mechanistic studies revealed that dual anti-OX40/IL-2c therapy significantly increased the proliferation (Ki-67) and differentiation (granzyme B) of anergic tumor-associated Ag-specific CD8 T cells, while reducing their expression of the senescence-associated molecule KLRG1 (Fig. 8B). The gene discussed is CD8A; the disease is neoplasm.